Labrys Biologics Snags $31M Series A, CEO and Pfizer MAb

Labrys Biologics Inc. burst on the biotech scene with a $31 million Series A, a new president and CEO and the acquisition of a Phase II-ready anti-calcitonin gene-related peptide (CGRP) humanized monoclonal antibody (MAb) from Pfizer Inc. to treat chronic migraine.